Viracta Therapeutics, a clinical-stage precision oncology company, has announced its participation in a series of investor conferences scheduled for November. In tandem with this announcement, Viracta Therapeutics’ stock is experiencing a notable surge in the market today.
At the time of this publication, Viracta Therapeutics Inc stock (VIRX) has witnessed a surge.
Viracta Therapeutics Inc
Current Price: $0.95
Change : +0.27
Change (%): (39.81%)
Volume: 509.5K
Source: Tomorrow Events Market Data
The company’s management will be presenting at three prominent events, providing a platform to showcase their advancements and engage with potential investors.
The first conference, the Stifel 2023 Healthcare Conference, is slated for Wednesday, November 15, 2023. The presentation is scheduled to take place from 10:20 AM to 10:50 AM Eastern Time.
Following this, Viracta Therapeutics will also feature at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023. The presentation is set for 12:10 PM to 12:30 PM Eastern Time.
On the subsequent day, Wednesday, November 29, 2023, the company will participate in the 6th Annual Evercore ISI HealthCONx Conference. The presentation is scheduled from 3:25 PM to 3:45 PM Eastern Time.
For those unable to attend in person, a live webcast of the presentations will be accessible on the Investors section of the Viracta website, specifically under the “Events and Webcasts” section. Additionally, the presentations will be archived for a duration of 90 days for reference.
The company’s stock performance over various timeframes indicates fluctuations in its value. Over the past five days, the stock has demonstrated a significant increase of 32.90%. Looking at a broader perspective, the performance over the course of one month has shown a growth of 18.48%.
However, it is important to note that over a three-month span, Viracta Therapeutics’ stock has experienced a decline of 39.09%. Year-to-date performance reflects a decrease of 40.76%. Over the course of the last year, the stock has seen a substantial decrease of 73.39%.
Viracta Therapeutics’ presence at these upcoming conferences not only signifies a platform for the company to showcase its latest developments but also provides an opportunity for potential investors to gain insight into the company’s innovative work in precision oncology. This engagement with the investment community is anticipated to further propel Viracta Therapeutics’ trajectory in the field of oncology research and treatment.
